Date | Price Target | Rating | Analyst |
---|---|---|---|
7/18/2022 | $17.00 | Outperform | Oppenheimer |
- Patients are preselected for CDKN2A and/or CDKN2B abnormalities - - Safety and efficacy data to be reported at an upcoming oncology medical conference - BERKELEY HEIGHTS, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative cancer medicines, today announced that enrollment of 12 patients has been completed as per protocol in Cohort 8 of its Phase 2 stage, proof of concept 065-101 study of fadraciclib ("fadra"), a CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma. Enrollment of Cohort 5 in patients with T-Cell Lymphoma is continuing.
BERKELEY HEIGHTS, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced it will be featured as a presenting company at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand. Spiro Rombotis,
BERKELEY HEIGHTS, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel") and a hearing has been scheduled for October, 15, 2024. The request automatically stays any suspension or delisting action pending the Panel's decision after the hearing and the expiration of any additional extension period granted by the Panel after the hearing. As previously reported, on August 26, 2024, the Listing Qualifications Staff
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer ("CMO") of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company. "We are delighted to have Brian join Cyclacel as CMO. His extensive clinical and product development experience in oncology and hematology further adds to the strengths of our team and will support our efforts
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures– BERKELEY HEIGHTS, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2020 achievements and outlining the Company’s key business objectives for 2021. The Company will present at Biotech Showcase™ Digital 2021 taking place virtually from Januar
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
Oppenheimer resumed coverage of Cyclacel Pharma with a rating of Outperform and set a new price target of $17.00
Oppenheimer initiated coverage of Cyclacel Pharmaceuticals with a rating of Outperform and set a new price target of $17.00
8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. Molecular Partners (NASDAQ:MOLN) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million. Longeveron (NASDAQ:LGVN) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million. TRACON Pharma (NASDAQ:TCON) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million. Oramed Pharmaceuticals (NASDAQ:ORMP) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million. NovaBay Pharm
Gainers Venus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 8.58% to $2.15. The market value of their outstanding shares is at $3.1 million. Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 8.27% to $0.59. The market value of their outstanding shares is at $6.0 million. Kiora Pharmaceuticals (NASDAQ:KPRX) shares rose 5.0% to $0.45. The market value of their outstanding shares is at $11.9 million. Fractyl Health (NASDAQ:GUTS) shares moved upwards by 4.94% to $6.79. The market value of their outstanding shares is at
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
- Oral Fadraciclib Phase 2 Proof of Concept Study Enrolling Well -- 065-101 PoC Interim Data Anticipated in the Fourth Quarter of 2024 -- Management to Host Conference Call at 4:30 pm EDT Today - BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today second quarter financial results and provided a business update. "Following oral fadraciclib data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the Phase 2 stage of our 065-101 study is enrolling well,
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2024 financial results on Wednesday, August 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call: (203) 518-9708 Archive: (800) 934-7884 / international archive: (402) 220-6987 Code for live and archived conference call is CYCCQ224. Webcast link For the live and archived webcast,
- New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib -- First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of Concept Study -- Balance Sheet Bolstered with $8.0 million Private Placement Priced At-The-Market Under Nasdaq Rules -- Management to Host Conference Call at 4:30 pm EDT Today - BERKELEY HEIGHTS, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today first quarter financial results and provided a business update
SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)